Reference is made to the stock exchange announcements published by Observe
Medical ASA (the "Company") on 21 February 2022, regarding the exercise of
subscription rights in the rights issue by certain primary insiders and a close
associate of a primary insider, and today, on 24 February 2022 regarding the
final results of the rights issue of 25,714,286 new shares in the Company (the
"Offer Shares") at a subscription price of NOK 7.00 per share (the "Rights
Issue").

Ingerø Reiten Investment Company AS ("IRIC"), a closely associated person of
Terje Bakken, chairman of the board of directors of the Company, has today, on
24 February 2022, been allocated and thereby validly subscribed for the 547,425
Offer Shares it over-subscribed in the Rights Issue. IRIC's total allocation and
subscription of Offer Shares in the Rights Issue was thus 5,714,286.

Per Arne Nygård, CFO of the Company, has today, on 24 February 2022, been
allocated and thereby validly subscribed for the 175,184 Offer Shares he over
-subscribed in the Rights Issue. Nygård's total allocation and subscription of
Offer Shares in the Rights Issue was thus 200,000.

Please see the attached notifications of trade for further information.

For further information about the Company, please contact:

Björn Larsson, CEO of Observe Medical,
Mobile: +46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com

Per Arne Nygård, CFO of Observe Medical,
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

For information about the Rights Issue, please contact the Managers:

Carnegie AS, tel.: +47 22 00 93 40
DNB Markets, tel.: +47 23 26 81 01

About Observe Medical

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders bacterial migration that can lead to urinary infections
(SippCoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.